Group 1 - The Hong Kong pharmaceutical stocks experienced a collective decline, with notable drops in specific companies [1] - Three-Sixty Pharmaceuticals (01530.HK) fell over 8%, indicating significant market pressure [1] - China Biopharmaceutical (01177.HK) decreased by more than 2%, reflecting a broader trend in the sector [1] Group 2 - Hansoh Pharmaceutical (03692.HK) and CSPC Pharmaceutical Group (01093.HK) both saw declines exceeding 1%, contributing to the overall downturn in the industry [1]

Group 1 - The core viewpoint of the article highlights the significant growth of E Fund's Hong Kong Stock Connect Quality Growth Mixed Fund C (017974), with a net asset increase of 230.89% to 287 million yuan as of March 31, 2025 [1] - The fund manager, Li Jianfeng, has an extensive background in investment banking and asset management, having worked with prestigious firms such as Goldman Sachs and UBS before joining E Fund in 2022 [1] - The fund's recent performance shows a 15.06% return over the past three months and a 29.17% return over the past year, with a cumulative return of 9.46% since inception [2] Group 2 - Recent changes in fund share scale indicate no subscriptions and minimal redemptions, with total shares remaining at 0.02 billion as of March 31, 2025, reflecting a net asset change rate of -2.54% [2] - The top ten stock holdings of the fund include Tencent Holdings, Pop Mart, Alibaba-W, China Mobile, and others, accounting for a total of 55.59% of the portfolio [2] - E Fund Management Co., Ltd. was established in April 2001, located in Zhuhai, with a registered capital of 132.442 million yuan [2]

消息面上，相关机构近期表示，创新药仍处于产业加速向上的周期，今年也有强基本面的兑现支撑。在 既往ADC、PD1/VEGF等技术爆发之后，TCE、ProTac等新技术已经看到萌芽开花；同时，创新药从可 预期的BD潮走向盈利潮，以往大家对创新药的疑虑是研究壁垒高、企业没盈利，因此不敢投，但随着 未来企业的收入高增速带动利润的快速提升，就进入了投资者可理解的范畴内。 港股创新药板块高盈利持续消化估值。港股创新药指数2月21日市盈率为64倍，4月24日最新市盈率仅为 27倍，不足两个月前的一半，当前布局性价比突出。 4月24日，港股市场低开震荡，港股创新药板块全面爆发。港股创新药指数成分股中，凯莱英涨超 17%，荣昌生物、亚盛医药-B、康方生物涨超7%，信达生物、联邦制药涨超6%，康龙化成、三生制药 涨超4%。港股创新药ETF（159567）连续2个交易日成交额超9亿元，市场关注度较高。 西南证券表示，创新药板块的投资价值在于其背后的新质生产力和高质量发展的大背景。随着各地政府 不断出台支持创新药的政策，如北京、深圳等地发布的支持创新药政策，这些政策不仅加强了对创新药 械研发、生产、审批、使用的全链条支持，还促进了健 ...

Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].

Investment Rating - The industry investment rating is "Outperform the Market" [1][50]. Core Insights - Eli Lilly's first oral small molecule GLP-1 drug, Orforglipron, has successfully completed Phase 3 clinical trials, which is expected to change the landscape of weight loss medications [3][4]. - The ACHIEVE-1 trial showed that Orforglipron significantly reduced HbA1c levels by 1.3% to 1.6% from a baseline of 8.0% after 40 weeks, with over 65% of patients achieving HbA1c levels ≤6.5% [3][4]. - Patients receiving the highest dose of Orforglipron lost an average of 7.3 kg, indicating potential for further weight loss [4]. - Eli Lilly plans to submit a global application for Orforglipron for weight management by the end of this year and for type 2 diabetes treatment in 2026 [4][5]. Summary by Sections Industry Overview - The successful Phase 3 trial of Orforglipron positions it as a potential second oral GLP-1 drug in the U.S., following Novo Nordisk's Rybelsus [5]. Investment Strategy - Focus on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [7]. - Recommended companies include innovative drug developers and those with strong overseas market potential [7]. Key Companies to Watch - **Nocera Health**: Expected to achieve over 1 billion yuan in revenue from its core product, with a projected 49% year-on-year growth [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [11]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [13]. - **Aier Eye Hospital**: Benefiting from increasing demand in ophthalmology and ongoing overseas expansion [22]. Market Performance - The pharmaceutical sector saw a decline of 0.36% last week, while the broader market index rose by 0.59% [25][36].

Group 1 - The core point of the article is that Sangfor Pharmaceutical's dual-specific antibody (code: 707) has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting first-line treatment for PD-L1 positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1][2] - Lung cancer has the highest incidence and mortality rates among all cancers, with non-small cell lung cancer accounting for approximately 80%-85% of all lung cancer cases [1] - Current treatments for NSCLC, including anti-PD-1/L1 monotherapy and combination chemotherapy, show limited effectiveness, with a 5-year survival rate of only 17%-30% [1] Group 2 - The dual-specific antibody 707 is developed based on the CLF2 patent platform and can simultaneously inhibit VEGF and PD-1, showing significant anti-tumor activity and good safety profile in clinical trials [1] - Sangfor Pharmaceutical is also advancing clinical research for 707 in other cancers such as colorectal cancer, endometrial cancer, and ovarian cancer, and has received FDA IND approval for 707 [2] - The company has partnered with BaiLi Tianheng to explore the potential of 707 in combination with BL-B01D1 for solid tumors in China, enhancing the application prospects of 707 [2]

（於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：01530） 自願公告 抗VEGF/PD-1雙特異性抗體藥物707注射液 獲國家藥品監督管理局突破性療法認定 本公告由三生制药（「本公司」，連 同 其 附 屬 公 司，統 稱（「三生制药」））自 願 刊 發。 三生制药自主研發的抗VEGF/PD-1雙特異性抗體（研 發 代 碼：707注 射 液）於2025年4 月17日 獲 國 家 藥 品 監 督 管 理 局 納 入 突 破 性 治 療 品 種，適 應 症 為 一 綫 治 療PD-L1表 達 陽 性 的 局 部 晚 期 或 轉 移 性 非 小 細 胞 肺 癌。 707注射液是三生制药基於CLF2專利平台自主開發的靶向VEGF/PD-1雙特異性抗 體，目 前 正 於 中 國 開 展 多 項 臨 床 研 究，其 中 一 綫 治 療PD-L1表達陽性的局部晚期 或轉移性非小細胞肺癌已獲國家藥監局藥品審評中心（「CDE」）批准開展III期臨床 研 究。此 外，707注 射 液 正 於 國 內 開 展 聯 合 化 療 一 綫 治 療 晚 期 非 小 細 胞 肺 癌、轉 移 性結直腸癌及晚期婦科 ...

Summary of Key Points from the Conference Call Industry Overview - The global pharmaceutical market is substantial, with an estimated size of approximately $1.5 trillion in 2023, projected to grow at a CAGR of 3%-6% from 2023 to 2027. The U.S. market accounts for nearly half of this, while emerging markets in the Asia-Pacific region are expected to grow at a faster rate. Notably, oncology and weight loss sectors are anticipated to see significant growth, providing important opportunities for pharmaceutical companies [3][5]. Internationalization of Chinese Pharmaceutical Industry - The internationalization process of the Chinese pharmaceutical industry can be categorized into three main parts: product export, technology export, and business model export. Product export can occur through self-sales, distributor agency (CSO model), and collaboration (BD model) [2]. - The internationalization stages include product registration, channel expansion, localization, and brand enhancement. Most Chinese innovative pharmaceutical companies are still in the product registration phase, with a few, like BeiGene and Mindray, advancing to channel expansion and localization [4]. Export Trends and Market Dynamics - China's pharmaceutical export scale reached $102 billion in 2023, with a notable increase in exports to Belt and Road countries, rising from 33% in 2013 to 37% in 2023. Conversely, the export proportion to the U.S. has decreased from 19% in 2010 to 16.7% in 2023 [7]. - The export of active pharmaceutical ingredients (APIs) from China is also on the rise, with an estimated $43 billion in exports in 2024, reflecting a nearly 5% year-on-year growth [3][9]. Company-Specific Highlights BeiGene - BeiGene's performance is strong, with sales of its drug, Zanubrutinib, expected to reach $2.6 billion in 2024, doubling year-on-year. The company anticipates achieving profitability in 2025, supported by a deepening product pipeline in hematological malignancies [3][20]. 3SBio - 3SBio is expected to see steady growth, with revenue and profit exceeding expectations in 2024, achieving over 15% growth. Key products like TPIAO and Mandy are maintaining high growth rates, with TPIAO projected to exceed $7 billion in revenue in 2024, a 20% increase [23][24]. Rongchang Biologics - Rongchang Biologics faces challenges with cash flow and sales but has seen significant growth in sales of its drug, Tislelizumab, which increased by 88% year-on-year. The company is enhancing cash flow through a private placement and expects to reduce losses significantly in the coming year [26][27]. Regulatory and Policy Environment - Recent updates in pharmaceutical policies indicate a shift towards optimizing procurement policies, focusing on quality assessment and regulation. The average price reduction from the tenth batch of generic drug procurement was around 50%-61%, with expectations for further reductions in future batches [14][15]. - The innovation policy landscape is supportive of the development of innovative medicines, with a focus on improving approval processes and market access [16][18]. Investment Recommendations - Recommended stocks for April include BeiGene, 3SBio, and Major Biologics, with BeiGene highlighted for its strong performance and growth potential [19][20]. Conclusion - The Chinese pharmaceutical industry is experiencing significant growth and internationalization, with key players like BeiGene and 3SBio showing promising performance. The evolving regulatory landscape and increasing focus on innovation are expected to drive future growth in the sector.

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [2] Core Insights - The Chinese innovative drug sector is entering a harvest period, with a focus on technological innovation and business development (BD) potential [5] - Companies such as Sangfor Biopharma, Kexing Pharmaceutical, and Yifang Biotech are highlighted for their strong growth prospects and innovative pipelines [4][5] Summary by Sections 1. Chinese Innovative Drugs Entering Harvest Period - **Sangfor Biopharma**: Core products are showing steady growth, and the innovative pipeline is gradually yielding results. The PD-1/VEGF dual antibody AK112 has become the first drug to outperform K drug in head-to-head Phase III clinical trials, enhancing the development enthusiasm for PD(L)-1/VEGF dual antibodies. The company has three ongoing clinical trials demonstrating excellent efficacy and BD potential [7][8] - **Kexing Pharmaceutical**: The CAR-T therapy shows significant potential, with its first product, CT053, approved for treating multiple myeloma in February 2024. Another product, CT041, is a potential first-in-class CAR-T for Claudin18.2, with a Phase II trial for gastric cancer completed. The company is well-positioned in the universal CAR-T technology space [11][12] - **Yifang Biotech**: The drug D-2570 shows promising data for treating psoriasis, with clinical results indicating significant efficacy compared to placebo. The drug is in Phase II trials and ranks third among domestic products, with a large patient population and a competitive landscape [14][15] 2. Weekly Market Review and Hotspot Tracking (March 31 - April 3, 2025) - The pharmaceutical and biotechnology sector index rose by 1.2%, outperforming the CSI 300 index by 2.57%. Year-to-date, the sector index has increased by 4.77%, also outperforming the CSI 300 index by 6.64 [16][18] - The top five performing stocks during this period included Duorui Pharmaceutical (up 56.32%), Weisi Medical (up 31.80%), and Hasanlian (up 31.15%) [29][32] 3. Overall Investment Strategy and Allocation Thoughts - The development of AI is driving the widespread adoption of AI in healthcare, with many medical companies exploring AI applications. Companies with extensive patient data and those with health insurance data are expected to have significant application potential. The report suggests focusing on innovative drugs and companies with a turning point in fundamentals [4][5]

Summary of the Conference Call for Sanofi Pharmaceutical Company Overview - Sanofi Pharmaceutical was founded in 1993 by General Lou Dan, with a military background contributing positively to its long-term development [3] - The company has evolved into a comprehensive pharmaceutical enterprise focusing on oncology, hematology, and consumer healthcare, achieving over 50% market share in key products [3][4] Core Business Insights - **Product Focus**: Sanofi's key products include Teibiao, Yipiao, and Yisai Pu, with a strong emphasis on innovation through self-research and business development (BD) [3][5] - **Clinical Trials**: The company is nearing completion of Phase II clinical trials for its PD-L1/VEGF dual antibody, which could significantly impact non-small cell lung cancer treatment [3][8] - **Sales Projections**: Teibiao is expected to exceed 5 billion yuan in sales for 2024, with further growth anticipated from new indications and lifted insurance restrictions [3][10] Innovation and R&D - **Strategic Investments**: Sanofi has made strategic investments in cutting-edge technologies such as IDFC, cell therapy, and CAR-T dual antibodies [3][5] - **Autoimmune Disease Focus**: The company is targeting well-validated overseas markers in autoimmune diseases, maintaining a competitive position in the market [6] Collaborations - Sanofi has partnered with BeiGene to co-develop PD-L1/VEGF dual antibodies and ADC combinations, aiming to replace existing first-line treatments [7] Consumer Healthcare - **Market Leadership**: The product Mandu has become the market leader in both hospital and retail settings, with projected sales of over 1.3 billion yuan in 2025 [11] - **New Product Launches**: Bever, for moderate acne, is expected to reach 500,000 prescriptions in North America in 2024, translating to approximately $300 million in sales [11] Financial Performance - **EPO Segment**: The EPO segment is projected to achieve an 8%-9% growth rate in the first half of 2024, with a long-acting second-generation product expected to be approved in late 2025 [10] - **Overall Growth Strategy**: Sanofi's strategy of focusing on major products ensures stable growth over the next 2-3 years, with new product launches expected to enhance revenue streams [10][12] Future Outlook - Sanofi's robust pipeline in oncology and consumer healthcare, along with its innovative strategies, positions the company favorably for future growth [12]